{'fraction_non_alphanumeric': 0.024070021881838075, 'fraction_numerical': 0.002188183807439825, 'mean_word_length': 5.450704225352113, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Generalized morphea in the setting of pembrolizumab

Pembrolizumab is a programmed cell death (PD-1) inhibitor approved for treatment of metastatic melanoma and other metastatic solid tumors. Pembrolizumab exerts antitumor effects via reactivation of the T-cell response. However, this can lead to a loss of self-tolerance with worsening or new-onset autoimmune disease. We describe a patient with generalized morphea following treatment with pembrolizumab.